Colorectal Cancer Screening and Preventive Healthcare Practices

Colorectal cancer remains a leading cause of morbidity and mortality worldwide, yet its trajectory can be substantially altered through systematic screening and preventive healthcare measures. Population-based programmes employ a range of modalities, including colonoscopy, flexible sigmoidoscopy and stool-based tests, to detect premalignant lesions and early-stage tumours in asymptomatic individuals. Screening guidelines have evolved to recommend initiation at age 50 and, in some settings, at age 45, with intervals determined by individual risk factors and previous findings. Quality of bowel preparation, endoscopic technique and polyp-removal practices directly influence detection rates and the necessity for repeat procedures. Complementary strategies—such as lifestyle modification, chemoprevention and risk stratification tools—are increasingly integrated to tailor screening schedules and maximise preventive impact. Despite clear clinical benefit, barriers related to cost, access and patient engagement persist, driving innovation in minimally invasive tests, digital health outreach and machine-assisted imaging to broaden uptake and reduce global disparities.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Colorectal Cancer Screening and Preventive Healthcare Practices publication trend

The graph below shows the total number of articles in colorectal cancer screening and preventive healthcare practices across all publications each year (not limited to Nature Index journals).

Technical terms

Colonoscopy: Endoscopic examination of the entire large bowel using a flexible tube with camera to detect and remove abnormal lesions.

Flexible sigmoidoscopy: Endoscopic inspection of the distal colon and rectum, often used as a less invasive screening modality.

Faecal occult blood test (FOBT): Laboratory assay detecting hidden blood in stool, serving as a non-invasive initial screen for colorectal pathology.

Adenoma: Benign glandular tumour of the colon that may progress to malignancy if untreated.

Sensitivity: Proportion of true positive cases correctly identified by a screening test or algorithm.

Specificity: Proportion of true negative cases correctly excluded by a screening test or algorithm.

References

1. Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations. BMC Health Services Research (2014).
2. Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. Healthcare (2019).
3. Impact of The Affordable Care Act’s Elimination of Cost-Sharing on the Guideline-Concordant Utilization of Cancer Preventive Screenings in the United States Using Medical Expenditure Panel Survey. Healthcare (2019).